Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3891 - EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC).


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  Colon and Rectal Cancer


Giulia Martini


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


G. Martini1, V. Belli2, P.P. Vitiello2, T. Troiani2, C. Cardone1, S. Napolitano1, N. Matrone1, V. Sforza2, R. Franco2, F. Morgillo2, D. Ciardiello3, E. Giunta4, V. De Falco3, N. Zanaletti4, P. Vitale4, E. Martinelli3, F. Ciardiello1

Author affiliations

  • 1 Dipartimento Medico-chirurgico Di Internistica Clinica E Sperimentale "f. Magrassi E A. Lanzara", Università degli Studi della Campania "Luigi Vanvitelli", 80131 - Naples/IT
  • 2 Dipartimento Medico-chirurgico Di Internistica Clinica E Sperimentale "f. Magrassi E A. Lanzara", Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
  • 3 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 4 Oncologia Ed Ematologia, Università della Campania "Luigi Vanvitelli", 80131 - NAPOLI/IT


Abstract 3891


EPHA2 tyrosine kinase receptor is implicated in cell growth, migration, and invasiveness in a wide range of cancers. We studied its role as a potential marker of resistance to anti-EGFR drugs in colorectal cancer (CRC). We previously demonstrated that EPHA2 was differently activated among a panel of CRC cell lines with primary and acquired resistance to cetuximab and the use of ALW-II-41-27 (EPHA2 selective inhibitor) in combination with cetuximab was able to revert this resistance in in vitro experiments (abstract presented at 2016 ESMO Congress in Copenhagen). Here we present the study on in vivo models.


EGFR dependent SW48 and LIM1215 cell lines were engrafted into nude mice and treated with cetuximab until disease progression. Once tumors became resistant (SW48-CR and LIM1215-CR) mice were randomized in groups of 10 mice each and assigned to receive ALW- II-41-27 as single agent or in combination with cetuximab, no treatment and cetuximab alone group served as control. ALW- II-41-27 was administered daily at 30 mg/kg by oral gavage and cetuximab intraperitoneally at 1 mg/kg two days a week. Treatment was performed for three weeks, then mice were euthanized and protein expression in tumors was analysed by Western Blot.


The combination of the two drugs induced a significant reduction of tumor volume since the first administration. A reduction of 50% of tumor volume was found in 5 out 10 LIM1215-CR mice treated with ALW-II-41-27 as single agent. This effect was maintained after cessation of therapy and induced prolonged survival. Tumor protein analysis by WB demonstrated a strong reduction of EPHA2 expression and activation in mice treated with the combination of ALW-II-41-27 and cetuximab, accompanied by a significantly inhibition of activated pMAPK and pAKT.


These results highlight the role of EPHA2 as a potential therapeutic target in mCRC treatment.

Clinical trial identification

Legal entity responsible for the study

Università della Campania Luigi Vanvitelli




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.